Hualan Biological Vaccine Inc. (SHE:301207)

China flag China · Delayed Price · Currency is CNY
19.25
-0.01 (-0.05%)
Apr 29, 2026, 3:04 PM CST
23.95%
Market Cap 11.46B
Revenue (ttm) 1.20B
Net Income (ttm) 187.51M
Shares Out 595.00M
EPS (ttm) 0.32
PE Ratio 61.12
Forward PE 53.50
Dividend 1.60 (8.23%)
Ex-Dividend Date Oct 27, 2025
Volume 3,328,028
Average Volume 5,501,348
Open 19.01
Previous Close 19.26
Day's Range 19.01 - 19.40
52-Week Range 15.55 - 27.88
Beta 0.77
RSI 45.82
Earnings Date Apr 27, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-drie... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 708
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301207
Full Company Profile

Financial Performance

In 2025, Hualan Biological Vaccine's revenue was 1.20 billion, an increase of 6.62% compared to the previous year's 1.13 billion. Earnings were 182.92 million, a decrease of -10.99%.

Financial Statements

News

There is no news available yet.